关键信息
-
基因名
Siglec-2/CD22
-
简介
The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Rat (669a.a, HEK293, His) is the recombinant rat-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Rat (669a.a, HEK293, His) is 669 a.a., with molecular weight of 100-150 kDa.
- 应用
-
别名
B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2
-
种属
Rat
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
D3ZD88
-
表达区间
W24-R692
-
分子量
100-150 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Siglec-2, also known as CD22, is a member of the sialic acid-binding immunoglobulin-like lectins (Siglecs) family, predominantly expressed on B cells. It plays a crucial role in modulating B cell activation, tolerance, and survival. Abnormalities in CD22 expression or function have been implicated in various autoimmune diseases and B cell malignancies. Research on Siglec-2/CD22 recombinant proteins has gained interest due to their potential as therapeutic targets in treating such conditions. These recombinant proteins can be used to explore the structure-function relationship of CD22, investigate its role in immune responses, and develop novel approaches for cancer immunotherapy. By engineering CD22 recombinant proteins, researchers aim to elucidate the mechanisms underlying CD22-mediated signaling and to identify ways to enhance or inhibit its activity, ultimately paving the way for targeted therapies in oncology and autoimmunity. The development of CD22-targeted agents, such as monoclonal antibodies or fusion proteins, has shown promise in clinical settings, offering new avenues for enhancing B cell-targeted treatments and improving patient outcomes.
